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Reviewed by: Dr. Valerie Zammit
Case summary:
Demographic details:
Patient: YB, Male.  
Resident in Attard. 
Age: 2 years
Referred by: GP
Patient YB is a two-year-old boy who presented to A&E with a 7 day history of fever up to 101.8oF 
associated with symptoms of an upper respiratory tract infection with cough, vomiting and diarrhoea and 
bilateral non-purulent conjunctivitis and fissuring of the lips. Based on clinical findings the patient was 
diagnosed with Kawasaki Disease and was treated accordingly.
Presenting complaint:
Pyrexia up to101.8oF: 7 days
Non-Purulent conjunctivitis: 7 days.
Cracked lips: 7 days.
History of presenting complaint:
The patient developed coryzal symptoms and cough associated with a temperature which persisted for 
7 days. He was also vomiting and passing loose stools. Concomitantly he developed a non-purulent 
conjunctivitis with fissuring and crusting of his lips. He was seen by the GP who prescribed an antibiotic, 
a mucolytic agent and antipyretics. However, the fever persisted with no clinical improvement and the 
patient was admitted to hospital.
Past medical and surgical history:
Past medical history:
Bronchiolitis: 7 weeks prior to current admission
Drug history:
Drug Dosage Frequency Type Reason
Augmentin
457mg/5ml
Syrup
2.5ml BD Penicillin 
Antibiotic
Treatment of 
secondary bacterial 
infection
Paracetamol
Suppositories
125-250mg 4-6 hourly Antipyretic 
and Analgesic
Brings about a 
reduction in fever
8Ambroxol 
hydrochloride 
Syrup
2.5ml TDS Mucolytic- 
cough 
preparation
Secretolytic agent 
and Mucolytic 
agent which helps 
in the breakdown 
and thinning of 
mucus. 
Table 11 Treatment on admission
The patient has no known drug allergy. 
Family history: 
Both parents are unrelated and healthy. There is no significant family history. 
Social history:
The boy has a fraternal twin sister, lives with his family and attends playschool. 
Systemic inquiry: 
• General Health: the patient was feverish and irritable.
• Cardiovascular System: nil of note
• Respiratory System: nil of note
• Gastrointestinal System: few episodes of vomiting, an episode of loose stools.
• Genitourinary System: the patient was passing normal volumes of urine.
• Central Nervous System: nil of note
• Musculoskeletal System: nil of note
• Endocrine System: nil of note
• Others: non-purulent conjunctivitis, mild cervical lymphadenopathy.
Discussion of results of general and specific examinations:
The patient was lying down in bed, miserable and irritable. He was not pale, jaundiced or cyanosed 
and was well-hydrated. There were no evident rashes. He had a normal respiratory rate. Mild cervical 
lymphadenopathy was noted.  His temperature was 101.8oF (febrile). There was no generalised oedema 
but the hands were noted to be swollen. The tonsils were enlarged with no pus but a generalised erythema 
of the oral mucosa was noted. Healing perioral excoriations and satellite lesions on the nose were evident. 
Cardiovascular examination revealed normal heart sounds S1+S2+0 and a pulse of 148 beats per minute 
of good volume. 
Respiratory examination showed equal air entry in both right and left lungs with normal vesicular breath 
sounds. No added sounds were noted. 
The abdomen moved with respiration and there were no swellings or scars. It was soft, with no guarding 
or rebound tenderness.  No masses were felt and there was no organomegaly.  Normal bowel sounds were 
auscultated and stools were normal. 
9Differential diagnosis: 
• Kawasaki Disease
• Stephen Johnson Disease
• Measles
• Scarlet Fever
• Drug reactions
• Other febrile viral exanthems
• Toxic Epidermal Necrolysis
• Rocky Mountain Spotted fever
• Staphylococcal Scalded skin Disease
• Juvenile Idiopathic Arthritis 
• Leptospirosis
• Mercury Poisoning 2
Diagnostic procedures:
Laboratory exams:3-4
Test: Complete blood count, including platelet count.
Justification for test: May help with differential diagnosis specifically assessing white blood cell count
                                  and differential, which is likely to be elevated and the presence of anaemia. A
                                  marked thrombocytosis in the second week of illness is a typical finding.
Result:  Normocytic anaemia, with an elevated white cell count and thrombocytosis. 
Conclusion: These results are often seen in Kawasaki Disease.
Test: Urea & Electrolytes
Justification for test: These tests help assess state of hydration and electrolyte imbalances. 
Result: Normal 
Conclusion: This excludes any Renal Disease. 
Test: C- Reactive Protein
Justification for test: Acute phase reactant. 
Result: Elevated
Conclusion: This is usually elevated to a degree not typically found in common viral infections and can
                     be an indication of Kawasaki disease or other invasive bacterial conditions. 
Test: Erythrocyte Sedimentation Rate
Justification for test: Nonspecific marker of inflammation.
Result: Elevated
Conclusion: This is usually elevated to a degree not typically found in common viral infections and can
                     help differentiate between connective tissue diseases and other bacterial infections.
Test: Blood cultures
Justification for test: This is done to detect the presence of actively multiplying bacteria or fungi in the
                                  bloodstream, to identify the microorganism(s) present and to guide antimicrobial
                                  treatment. 
Result: Negative
Conclusion:  Bacterial sepsis is excluded. 
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Instrumental exams:
Test: Echocardiogram (ECHO) 2-3,5
Justification for test: Kawasaki Disease affects the coronary arteries in 1/3 of affected children within the
                                  first 6 weeks of illness leading to aneurysm formation. These are best visualised           
                                  by echocardiography. In the acute phase of illness, coronary artery abnormalities        
                                  include lack of tapering, perivascular brightness and ectasia. Echocardiography  
                                  may also reveal decreased ventricular function, mild valvular regurgitation and        
                                  pericardial effusion. 
Result: The ECHO was found to be normal. Mitral, coronary or cardiac involvement was excluded.
Conclusion: The disease did not involve the coronary arteries in this patient. 
Therapy:
Drugs:1
Drug Dosage Frequency Type Reason
Immunoglobulin  2g/kg IVI 2 g/kg over 10 
hours; preferably 
within the first 10 
days of the illness 
Human pooled 
Immunoglobulin
Suppresses 
inflammatory 
response which may 
lead to coronary 
artery damage
Paracetamol
Suppositories
250mg PR Every 4-6 hours Antipyretic and 
analgesic
Provides 
symptomatic relief
Aspirin Tablets 7.5 -12.5 mg/
kg/dose = 150 
mg PO
QDS for 2 weeks or 
until afebrile; dose 
reduced to 2-5mg/
kg od for 6-8 wk
NSAID 
Anti -Inflammatory
Antiplatelet and 
anti-inflammatory 
effect preventing 
coronary artery 
damage
Ranitidine
Syrup 25mg/ml
2-4 mg/kg/dose 
= 4mls  PO
BD Histamine H2- 
receptor antagonist
This is used as 
prophylaxis against  
dyspepsia and risk 
of gastrointestinal 
bleeding caused by 
high dose aspirin
Diagnosis: 
Kawasaki Disease is a systemic vasculitis which predominantly affects children under the age of 5 years. 
The etiology of Kawasaki disease remains unknown, although an infectious agent is strongly suspected 
based on clinical and epidemiologic features.  The diagnosis of Kawasaki Disease cannot be made by a 
single laboratory test or combination of tests. Physicians make the diagnosis after carefully examining a 
child, observing signs and symptoms and eliminating the possibility of other, similar diseases.  
To diagnose Kawasaki Disease the child must have a persistent fever of 5 days and 4 out of 5 of the 
criteria below:
• Polymorphous rash
• Bilateral (non-purulent) conjunctival injection
• Mucous membrane changes, e.g. reddened or dry cracked lips, strawberry tongue, diffuse redness 
of oral or pharyngeal mucosa
• Peripheral changes, e.g. erythema of the palms or soles, oedema of the hands or feet, and in 
convalescence desquamation
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• Cervical lymphadenopathy (> 15 mm diameter, usually unilateral, single, non-purulent and painful).
In this case the child presented with a 7 day history of fever, a bilateral conjunctival injection, 
cracked lips, swollen hands and cervical lymphadenopathy and therefore fulfilled the criteria of 
diagnosis of Kawasaki Disease2-3,5-7. 
Final treatment and follow up: 
The patient was treated as shown in Table 2. He was also prescribed intravenous fluids - 5% dextrose in 
0.9% saline at maintenance rate. These intravenous solutions are indicated for use in paediatric patients 
as sources of electrolytes, calories and water for hydration 8. Oral fluids were encouraged and the patient 
was placed on a soft diet. 
Renal profile tests were carried out and repeated as necessary. Parameters including fluid input and output 
were monitored at regular intervals.
Since no coronary artery abnormalities were noted at presentation, an echocardiogram is to be repeated 
at two weeks and at six to eight weeks after diagnosis2. The risk of developing significant heart disease 
is less once the fever subsides3. 
The patient was kept in hospital until the fever subsided. He was then discharged and reviewed at regular 
intervals. 
The patient should be re-evaluated one week post-discharge and then have a repeat echocardiogram3. 
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Fact Box 2:
Name of Condition:  Kawasaki Disease5,6,7
Also known as: Mucocutaneous lymph node Disease; Infantile polyarteritis
Risk factors: 
• Age: Children under 5 years old are most at risk of Kawasaki Disease. 
• Sex: Boys are slightly more likely than girls are to develop Kawasaki Disease. 
• Ethnicity: Children of Asian descent, such as Japanese or Korean, have higher rates of Kawasaki 
Disease. 
Symptoms and Signs: 
Children with Kawasaki Disease usually present with:
• A persistent fever of 5 days and 4 out of 5 of the criteria below:
• Polymorphous rash
• Bilateral (non-purulent) conjunctival injection
• Mucous membrane changes, e.g. reddened or dry cracked lips, strawberry tongue, diffuse redness 
of oral or pharyngeal mucosa
• Peripheral changes, e.g. erythema of the palms or soles, oedema of the hands or feet, and in 
convalescence desquamation
• Cervical lymphadenopathy (> 15 mm diameter, usually unilateral, single, non-purulent and painful)
Prevention: Kawasaki Disease cannot be prevented, but usually has tell-tale symptoms and signs that 
appear in phases. 
Complications : Heart complications include: 
• Inflammation of the heart muscle (myocarditis) 
• Heart valve problems (mitral regurgitation) 
• Abnormal heart rhythm (dysrhythmia) 
• Inflammation of blood vessels (vasculitis), usually the coronary arteries, that supply blood to the 
heart 
For a small percentage of children with Kawasaki Disease, this can result in death in spite of treatment. 
Treatment: 
Immunoglobulins: Infusion of an immune protein (gamma globulin) through a vein (intravenously) can 
lower the risk of coronary artery problems 9. 
Aspirin: High doses of aspirin may help treat inflammation. Aspirin can also decrease pain and joint 
inflammation, as well as reduce the fever. Kawasaki treatment is a rare exception to the rule against 
aspirin use in children. 
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